Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losmapimod in FSHD
NCT04264442Phase 2Terminated
- Sponsor
- Fulcrum Therapeutics
- Start
- Feb 2020
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD), sponsored by Fulcrum Therapeutics. Primary endpoints: Serious Treatment Emergent Adverse Events at 57 months, Treatment Emergent Adverse Events at 57 months and 7 more. Started Feb 2020; status: terminated.
02
Drugs
losmapimod
03
Conditions
facioscapulohumeral muscular dystrophy (FSHD)
Beyond the preview
Go deeper on NCT04264442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04264442.